Q-omics provides the consensus-scored PADI4 profile across patient tissues and cancer cell-line models. PADI4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, PADI4 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PADI4 protein abundance shows 28,507 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight LUSC, KIRC, and PDAC as cancer lineages where PADI4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PADI4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PADI4 survival associations across molecular data types. PADI4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PADI4 RNA expression–survival associations across cancer types. High PADI4 expression shows unfavorable associations in LUSC, THCA, CESC and ESCA, but favorable associations in CHOL and SCLC. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify LUSC as the clearest survival context for PADI4 RNA expression.
This table summarizes PADI4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PADI4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PADI4 shows lower tumor expression in LUSC, LUAD, LIHC, KICH and BRCA and higher tumor expression in KIRC. The KIRC box plot shows higher PADI4 RNA expression in tumor versus normal tissue (log2 FC = +0.210, t-test p < 0.001).
This table shows molecular features associated with PADI4 in patient tissues and cancer cell lines. In patient samples, PADI4 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PADI4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
